Quantcast

Latest Diabetes management Stories

2014-06-16 08:27:42

Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGR(Rx) in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population (PP) treated with ISIS-GCGR(Rx) in addition to metformin achieved absolute mean reduction in hemoglobin...

2014-06-15 16:20:33

CONSISTENT 1 Trial Results Presented in Late-Breaker Poster SAN DIEGO, June 15, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th Scientific Sessions of the American Diabetes Association in San Francisco. The CONSISTENT 1 trial is evaluating Hylenex(®) recombinant and a new formulation of Hylenex currently under U.S. Food and Drug Administration (FDA) review, when used as...

2014-06-15 16:20:24

- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs. empagliflozin or linagliptin alone after 24 weeks RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2014 /PRNewswire/ -- Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly...

2014-06-15 15:18:02

The Endocrine Society Study suggests metformin controls blood sugar more effectively in African-Americans African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). An estimated 29 million Americans have diabetes. African Americans are twice as likely to...

2014-06-15 08:21:29

-- The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels between 10-12%. BOSTON, June 15, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial...

smartphone diabetes control
2014-06-15 06:15:40

redOrbit Staff & Wire Reports - Your Universe Online Researchers from the Scripps Whittier Diabetes Institute have devised a new text message program which they claim could help patients control their diabetes by sending them information about proper nutritional habits, the benefits of physical activities and reminders to check blood sugar on a regular basis. The program is part of the Dulce Digital study, and initial results suggest a text message-based self-management intervention...

2014-06-14 12:21:12

Results from Clinical Study in Type 2 Diabetes Patients with Renal Impairment and Preclinical Study in Type 1 Diabetes THE WOODLANDS, Texas, June 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), presented data at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through...

2014-06-14 12:21:08

PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus(®) (insulin glargine). Lowering of post-prandial glucose was measured as change...

2014-06-14 12:20:58

During the 1-year program, patients showed statistically significant reductions in blood glucose levels, increased belief in their ability to self-manage their diabetes and improved perceptions of support, while the community showed statistically significant increases in diabetes awareness SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- The American Academy of Family Physicians Foundation announced today that the Cities for Life program, supported by Sanofi US, helped decrease blood glucose...

2014-06-14 12:20:45

Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c) across both arms.(1) The head-to-head study compared...


Latest Diabetes management Reference Libraries

Diabetes Care
2012-05-12 21:41:27

Diabetes Care is a peer-reviewed medical journal established in 1978 and published monthly by the American Diabetes Association. It covers research in the following five categories: clinical care/education/nutrition/psychosocial research; epidemiology/health services research; emerging treatments and technologies; pathophysiology/complications; and cardiovascular and metabolic risk. The journal also publishes clinically relevant review articles, letters to the editor, and commentaries....

More Articles (1 articles) »
Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related